Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). CPBIO Holding Co's share price for the quarter that ended in Dec. 2025 was HK$7.26. CPBIO Holding Co's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 241 Mil. Therefore, CPBIO Holding Co's market cap for the quarter that ended in Dec. 2025 was HK$1,748 Mil.
CPBIO Holding Co's quarterly market cap
increased
from Jun. 2025 (HK$883 Mil) to Sep. 2025 (HK$2,049 Mil) but then
declined
from Sep. 2025 (HK$2,049 Mil) to Dec. 2025 (HK$1,748 Mil).
CPBIO Holding Co's annual market cap
increased
from Dec. 2023 (HK$229 Mil) to Dec. 2024 (HK$359 Mil) and
increased
from Dec. 2024 (HK$359 Mil) to Dec. 2025 (HK$1,748 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. CPBIO Holding Co's Enterprise Value for Today is HK$2,621 Mil.
CPBIO Holding Co (HKSE:03839) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
CPBIO Holding Co Market Cap Related Terms
CPBIO Holding Co Market Cap Historical Data
* Premium members only.
The historical data trend for CPBIO Holding Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CPBIO Holding Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CPBIO Holding Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CPBIO Holding Co's Market Cap distribution charts can be found below:
* The bar in red indicates where CPBIO Holding Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
CPBIO Holding Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CPBIO Holding Co (HKSE:03839) has a Market Cap of HK$2,213 Mil as of Aug. 05, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CPBIO Holding Co and its competitors. According to the industry distribution chart, CPBIO Holding Co ranks #493 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 48.1%.
Is CPBIO Holding Co's Market Cap too high?
CPBIO Holding Co's current Market Cap is HK$2,213 Mil. Based on the distribution chart, CPBIO Holding Co ranks #493 out of 1024 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, CPBIO Holding Co has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CPBIO Holding Co's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CPBIO Holding Co ranks #493 out of 1024 companies for Market Cap. This puts CPBIO Holding Co in the upper half of its industry. The industry median Market Cap is 217.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 217.15, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CPBIO Holding Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 217.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CPBIO Holding Co's current Market Cap is HK$2,213 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CPBIO Holding Co stock overvalued right now?
Based on GuruFocus' analysis, CPBIO Holding Co (HKSE:03839) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$4.36, compared to a current price of HK$9.20 — trading 110.9% above its estimated fair value. The current Market Cap is HK$2,213 Mil. CPBIO Holding Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For CPBIO Holding Co (HKSE:03839), the current Market Cap is HK$2,213 Mil as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CPBIO Holding Co (HKSE:03839) Overvalued in 2026?
Based on GuruFocus' analysis, CPBIO Holding Co stock appears to be overvalued.
The current stock price of HK$9.20 is trading 110.9% above its estimated GF Value™ of HK$4.36.
GuruFocus considers CPBIO Holding Co to be Significantly Overvalued.
Key valuation signals for HKSE:03839:
Market Cap: HK$2,213 Mil
GF Value™: HK$4.36 vs. price of HK$9.20 (110.9% above fair value)
No single metric tells the full story. See the HKSE:03839 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chia Tai Enterprises International Ltd is engaged in the manufacture and sale of animal health products and chlortetracycline (CTC). The group has two reportable segments: Biotech Business and Investment Business. The Biotech Business segment is involved in the manufacture and/or sale of animal health products and chlortetracycline. The Investment Business segment is engaged in the trading of machinery and the manufacture and sale of automotive parts through the group's joint ventures and associates. It generates the majority of its revenue from the Biotech Business segment. Its geographical segments are Mainland China, which generates key revenue, Asia Pacific (excluding mainland China), the Americas, Europe, and Others.
71GF Score
Get the complete analysis for HKSE:03839
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03839 has been successfully added to your 
